

applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 25, 2019.

**ADDRESS:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on June 19, 2019, Cambrex High Point, Inc., 4180 Mendenhall Oaks Parkway, High Point, North Carolina 27265-8017 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II

The company plans to manufacture the above listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Dated: August 9, 2019.

**Neil D. Doherty,**

*Acting Assistant Administrator.*

[FR Doc. 2019-18324 Filed 8-23-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Application: Clinical Supplies Management Holdings, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk importers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 25, 2019. Such persons may also file a written request for a hearing on the application on or before September 25, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug

Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on June 5, 2019, Clinical Supplies Management Holdings, Inc., 342 42nd Street South, Fargo, North Dakota 58103 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I

The company plans to import listed controlled substances in their finished dosage form for use in clinical trials only. Drug codes 7350 (marihuana extract) and 7360 (marihuana) will be used for the manufacture of cannabidiol only.

Dated: August 9, 2019.

**Neil D. Doherty,**

*Acting Assistant Administrator.*

[FR Doc. 2019-18320 Filed 8-23-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration AMPAC Fine Chemicals Virginia, LLC**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below have applied for and been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various basic classes of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of scheduled II controlled substances. Information on a previously published notice is listed below. No comments or objections were submitted for this notice.

Company	FR docket	Published
AMPAC Fine Chemicals Virginia, LLC.	84 FR 21810	May 15, 2019.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to

manufacture the applicable various basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: August 9, 2019.

**Neil D. Doherty,**

*Acting Assistant Administrator.*

[FR Doc. 2019-18325 Filed 8-23-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 25, 2019.

**ADDRESS:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 15, 2019, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144-2951 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana .....	7360	I
Tetrahydrocannabinols ..	7370	I
Amphetamine .....	1100	II
Lisdexamfetamine .....	1205	II
Pentobarbital .....	2270	II
4-Anilino-N-phenethyl-4-piperidine (ANPP).	8333	II
Codeine .....	9050	II